Marginal-zone lymphoma

Andrés J M Ferreri, Emanuele Zucca

Research output: Contribution to journalArticle

Abstract

The term marginal-zone lymphoma (MZL) encompasses three closely related lymphoma subtypes, namely the "low-grade B-cell lymphoma of MALT type" currently named MALT lymphoma, the "nodal marginal-zone B-cell lymphoma" and a provisional entity in the REAL classification named "primary splenic MZL with or without villous lymphocytes". These entities display different characteristics, with evident clinical and biological variations according to the organ where the lymphoma arises. Marginal-zone B-cells are functionally heterogeneous and may differ with respect to the pattern of somatic hypermutation in their Ig variable genes. Sequence and mutation analysis of the rearranged Ig heavy chain variable genes and that somatic mutations pattern indicate that MZL may arise from different subsets of marginal-zone B-cells. Pathogenesis of these groups of lymphomas is correlated to chronic infections, like Helicobacter pylori, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci and Borrelia burgdorferi. Several therapeutic strategies against these malignancies exist. Surgical resection, radiotherapy and alkylating agent-based chemotherapy constitute standard approaches, while antimicrobial therapies, anti-CD20 therapy and new forms of immunotherapy constitute interesting experimental approaches. However, prospective trials on these malignancies are rare and universally accepted therapeutic guidelines do not exist. MZLs constitute an exciting investigational setting both from molecular and clinical points of view.

Original languageEnglish
Pages (from-to)245-256
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume63
Issue number3
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Lymphoma
Marginal Zone B-Cell Lymphoma
B-Lymphocytes
Chlamydophila psittaci
Immunoglobulin Heavy Chains
Immunoglobulin Genes
Mutation
Campylobacter jejuni
Borrelia burgdorferi
Alkylating Agents
B-Cell Lymphoma
Therapeutics
Helicobacter pylori
Hepacivirus
Non-Hodgkin's Lymphoma
Immunotherapy
Sequence Analysis
Neoplasms
Radiotherapy
Guidelines

Keywords

  • Borrelia burgdorferi
  • Chlamydia psittaci
  • Helicobacter pylori
  • Hepatitis C virus
  • MALT

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Marginal-zone lymphoma. / Ferreri, Andrés J M; Zucca, Emanuele.

In: Critical Reviews in Oncology/Hematology, Vol. 63, No. 3, 09.2007, p. 245-256.

Research output: Contribution to journalArticle

Ferreri, Andrés J M ; Zucca, Emanuele. / Marginal-zone lymphoma. In: Critical Reviews in Oncology/Hematology. 2007 ; Vol. 63, No. 3. pp. 245-256.
@article{bda5e1866a1d4b4f9ee515de9e9776da,
title = "Marginal-zone lymphoma",
abstract = "The term marginal-zone lymphoma (MZL) encompasses three closely related lymphoma subtypes, namely the {"}low-grade B-cell lymphoma of MALT type{"} currently named MALT lymphoma, the {"}nodal marginal-zone B-cell lymphoma{"} and a provisional entity in the REAL classification named {"}primary splenic MZL with or without villous lymphocytes{"}. These entities display different characteristics, with evident clinical and biological variations according to the organ where the lymphoma arises. Marginal-zone B-cells are functionally heterogeneous and may differ with respect to the pattern of somatic hypermutation in their Ig variable genes. Sequence and mutation analysis of the rearranged Ig heavy chain variable genes and that somatic mutations pattern indicate that MZL may arise from different subsets of marginal-zone B-cells. Pathogenesis of these groups of lymphomas is correlated to chronic infections, like Helicobacter pylori, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci and Borrelia burgdorferi. Several therapeutic strategies against these malignancies exist. Surgical resection, radiotherapy and alkylating agent-based chemotherapy constitute standard approaches, while antimicrobial therapies, anti-CD20 therapy and new forms of immunotherapy constitute interesting experimental approaches. However, prospective trials on these malignancies are rare and universally accepted therapeutic guidelines do not exist. MZLs constitute an exciting investigational setting both from molecular and clinical points of view.",
keywords = "Borrelia burgdorferi, Chlamydia psittaci, Helicobacter pylori, Hepatitis C virus, MALT",
author = "Ferreri, {Andr{\'e}s J M} and Emanuele Zucca",
year = "2007",
month = "9",
doi = "10.1016/j.critrevonc.2007.04.009",
language = "English",
volume = "63",
pages = "245--256",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Marginal-zone lymphoma

AU - Ferreri, Andrés J M

AU - Zucca, Emanuele

PY - 2007/9

Y1 - 2007/9

N2 - The term marginal-zone lymphoma (MZL) encompasses three closely related lymphoma subtypes, namely the "low-grade B-cell lymphoma of MALT type" currently named MALT lymphoma, the "nodal marginal-zone B-cell lymphoma" and a provisional entity in the REAL classification named "primary splenic MZL with or without villous lymphocytes". These entities display different characteristics, with evident clinical and biological variations according to the organ where the lymphoma arises. Marginal-zone B-cells are functionally heterogeneous and may differ with respect to the pattern of somatic hypermutation in their Ig variable genes. Sequence and mutation analysis of the rearranged Ig heavy chain variable genes and that somatic mutations pattern indicate that MZL may arise from different subsets of marginal-zone B-cells. Pathogenesis of these groups of lymphomas is correlated to chronic infections, like Helicobacter pylori, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci and Borrelia burgdorferi. Several therapeutic strategies against these malignancies exist. Surgical resection, radiotherapy and alkylating agent-based chemotherapy constitute standard approaches, while antimicrobial therapies, anti-CD20 therapy and new forms of immunotherapy constitute interesting experimental approaches. However, prospective trials on these malignancies are rare and universally accepted therapeutic guidelines do not exist. MZLs constitute an exciting investigational setting both from molecular and clinical points of view.

AB - The term marginal-zone lymphoma (MZL) encompasses three closely related lymphoma subtypes, namely the "low-grade B-cell lymphoma of MALT type" currently named MALT lymphoma, the "nodal marginal-zone B-cell lymphoma" and a provisional entity in the REAL classification named "primary splenic MZL with or without villous lymphocytes". These entities display different characteristics, with evident clinical and biological variations according to the organ where the lymphoma arises. Marginal-zone B-cells are functionally heterogeneous and may differ with respect to the pattern of somatic hypermutation in their Ig variable genes. Sequence and mutation analysis of the rearranged Ig heavy chain variable genes and that somatic mutations pattern indicate that MZL may arise from different subsets of marginal-zone B-cells. Pathogenesis of these groups of lymphomas is correlated to chronic infections, like Helicobacter pylori, hepatitis C virus, Campylobacter jejuni, Chlamydia psittaci and Borrelia burgdorferi. Several therapeutic strategies against these malignancies exist. Surgical resection, radiotherapy and alkylating agent-based chemotherapy constitute standard approaches, while antimicrobial therapies, anti-CD20 therapy and new forms of immunotherapy constitute interesting experimental approaches. However, prospective trials on these malignancies are rare and universally accepted therapeutic guidelines do not exist. MZLs constitute an exciting investigational setting both from molecular and clinical points of view.

KW - Borrelia burgdorferi

KW - Chlamydia psittaci

KW - Helicobacter pylori

KW - Hepatitis C virus

KW - MALT

UR - http://www.scopus.com/inward/record.url?scp=34547216863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547216863&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.04.009

DO - 10.1016/j.critrevonc.2007.04.009

M3 - Article

C2 - 17583528

AN - SCOPUS:34547216863

VL - 63

SP - 245

EP - 256

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -